Patents Examined by Bong-Sook Baek
  • Patent number: 11992487
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: May 28, 2024
    Assignee: Neurodon Corporation
    Inventor: Russell Dahl
  • Patent number: 11992491
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: May 28, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Ruth Boehni Stamm, Fritz Blatter, Martin Szelagiewicz
  • Patent number: 11963955
    Abstract: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: April 23, 2024
    Assignee: Texas Southern University
    Inventor: Omonike A. Olaleye
  • Patent number: 11930811
    Abstract: There is provided an antiviral vinyl-chloride-based resin composition including: 100 parts by weight of a poly(vinyl chloride)-based resin obtained by mixing 10-90 parts by weight of a vinyl-chloride-based resin for paste with 90-10 parts by weight of a suspension vinyl-chloride-based resin; and 0.5-10.0 parts by weight of a sulfonic-acid-based surfactant.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: March 19, 2024
    Assignee: Lonseal Corporation
    Inventor: Hiroki Matsumoto
  • Patent number: 11925195
    Abstract: The present invention disclosed herein relates to synergistic compositions for cerebrovascular diseases. In particular, the invention relates to synergistic, efficient, composition for treating cerebral ischemia or stroke comprising specific combination of standardized celery seed extract (CSE) enriched with Dl-3-N-Butylphthalide (NBP) and SIRT1 activators, wherein D1-3-N-Butylphthalide (NBP) and SIRT1 activator are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.
    Type: Grant
    Filed: October 31, 2020
    Date of Patent: March 12, 2024
    Assignee: CELAGENEX RESEARCH (INDIA) PVT. LTD.
    Inventors: Jotiram Palkar, Rajendra Prasad Tongra
  • Patent number: 11925704
    Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: March 12, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip P. Mehta, Henil Alpeshbhai Patel, Jayanta Kumar Mandal
  • Patent number: 11912677
    Abstract: A compound 1,3-benzothiazol-2-yl-N?-[(3-phenylprop-2-enoyl)oxy]ethanimidamide, its synthesis, and its use as an anticancer and/or antimicrobial agent.
    Type: Grant
    Filed: August 30, 2023
    Date of Patent: February 27, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Doaa H. Amed
  • Patent number: 11911364
    Abstract: The present invention provides new GABAA receptor-binding compounds that modify the activation of GABAA, their use in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: February 27, 2024
    Assignee: PEPTICOM LTD.
    Inventors: Immanuel Lerner, Amit Michaeli
  • Patent number: 11896577
    Abstract: The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: February 13, 2024
    Assignee: Mydecine Innovations Group Inc.
    Inventors: Denton W. Hoyer, Robert F. Roscow, Rong Ling, Chuanjun Gao
  • Patent number: 11890268
    Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: February 6, 2024
    Assignee: Saint Louis University
    Inventors: Ryan D. McCulla, Ankita Isor, Christopher Kent Arnatt
  • Patent number: 11890279
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: February 6, 2024
    Assignee: Neurodon Corporation
    Inventor: Russell Dahl
  • Patent number: 11878023
    Abstract: Provided herein are compositions and methods for treating pulmonary hypertension. In particular, provided herein are dry powder formulations of fasudil for delivery to the lung.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 23, 2024
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Heidi M. Mansour, Stephen Black, Priyadarshini Muralidharan
  • Patent number: 11877999
    Abstract: Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: January 23, 2024
    Assignees: THE TRUSTEES OF INDIANA UNIVERSITY, KOVINA THERAPEUTICS, INC
    Inventors: Elliot J. Androphy, Samy Meroueh, Zhijian Lu, Anne Rietz
  • Patent number: 11865183
    Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: January 9, 2024
    Assignee: POLYTHERICS LIMITED
    Inventors: Antony Godwin, Andrew Kyle, Nicholas Evans
  • Patent number: 11851413
    Abstract: A compound 1,3-benzothiazol-2-yl-N?-[(naphthalene-1-carbonyl)oxy]ethanimidamide compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: December 26, 2023
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhaim Ahmed, Amer A. Amer, Doaa H. Ahmed
  • Patent number: 11827626
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 28, 2023
    Assignee: NEURODON CORPORATION
    Inventor: Russell Dahl
  • Patent number: 11819505
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: July 18, 2022
    Date of Patent: November 21, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Brent Douty, Song Mei
  • Patent number: 11819568
    Abstract: Embodiments of the disclosure relate to dosage forms intended for smoking, vaporization and/or inhalation and to methods for the preparations thereof.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: November 21, 2023
    Assignee: TRICHOMESHELL LTD.
    Inventors: Guy Shibaz, Dror Shalitin, Gilad Asher Livni, Shay Avraham Sarid
  • Patent number: 11795190
    Abstract: Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.
    Type: Grant
    Filed: December 29, 2018
    Date of Patent: October 24, 2023
    Assignees: NATIONAL RESEARCH COUNCIL OF CANADA, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Janelle Sauvageau, Andrew Cox, Xinyi Guo, Scott Gray-Owen
  • Patent number: 11779553
    Abstract: Provided herein is a drug eluting device that can be implanted into the Muller's muscle of a subject to elute a sympathetic stimulant such as oxymetazoline, phenylephrine, norepinephrine, adrenaline, or a combination thereof. Also provided herein are methods to use the device and sympathetic stimulant to treat or prevent eyelid ptosis.
    Type: Grant
    Filed: November 28, 2022
    Date of Patent: October 10, 2023
    Inventor: Atif B. D. Collins